Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Union Pacific Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Union Pacific Corporation trades at $281.27 (market cap $168.09B). The key difference: Union Pacific Corporation is far larger — about 37.4× ACADIA Pharmaceuticals Inc.'s market cap, and Union Pacific Corporation pays a 1.95% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | UNP | |
|---|---|---|
Market Cap | $4.49B | $168.09B |
Sector | Health | Industrials |
52-Week High | $28.06 | $283.12 |
52-Week Low | $20.06 | $214.91 |
Enterprise Value | $3.69B | $198.56B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Union Pacific (UNP) trades at $283.12, up 0.31% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.93, and maintains robust profitability with a 29.2% net margin. Recent news highlights the ongoing merger process with Norfolk Southern and a class action lawsuit regarding environmental concerns.
Outlook remains positive with a consensus price target of $290.55, indicating potential upside. Key risks include regulatory scrutiny of the merger and legal challenges. The stock's valuation multiples are elevated, but solid cash flow and dividend growth support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
